A Rac1-Independent Role for P-Rex1 in Melanoblasts  by Lindsay, Colin R. et al.
REFERENCES
Bardin N, Anfosso F, Masse´ JM, et al. (2001)
Identification of CD146 as a component
of the endothelial junction involved in the
control of cell-cell cohesion. Blood 98:
3677–84
Dagur PK, Biancotto A, Wei L, et al. (2011)
MCAM-expressing CD4(þ ) T cells in
peripheral blood secrete IL-17 A and
are significantly elevated in inflammatory
autoimmune diseases. J Autoimmun 37:
319–27
Dagur PK, Tatlici G, Gourley M, et al. (2010)
CD146þ T lymphocytes are increased in
both the peripheral circulation and in
the synovial effusions of patients with various
musculoskeletal diseases and display pro-
inflammatory gene profiles. Cytometry B Clin
Cytom 78:88–95
Elshal MF, Khan SS, Raghavachari N, et al. (2007)
A unique population of effector memory
lymphocytes identified by CD146 having a
distinct immunophenotypic and genomic pro-
file. BMC Immunol 8:29
Elshal MF, Khan SS, Takahashi Y et al. (2005)
CD146 (Mel-CAM), an adhesion marker of
endothelial cells, is a novel marker of lym-
phocyte subset activation in normal periph-
eral blood. Blood 106:2923–4
Guezguez B, Vigneron P, Lamerant N et al. (2007)
Dual role of melanoma cell adhesion mole-
cule (MCAM)/CD146 in lymphocyte endothe-
lium interaction: MCAM/CD146 promotes
rolling via microvilli induction in lymphocyte
and is an endothelial adhesion receptor.
J Immunol 179:6673–85
Kagami S, Rizzo HL, Lee JJ et al. (2010) Circulating
Th17, Th22, and Th1 cells are increased in
psoriasis. J Invest Dermatol 130:1373–83
Larochelle C, Cayrol R, Kebir H et al. (2012)
Melanoma cell adhesion molecule identifies
encephalitogenic T lymphocytes and pro-
motes their recruitment to the central nervous
system. Brain 135(Part 10):2906–24
Mehta NN, Yu Y, Saboury B et al. (2011) Systemic
and vascular inflammation in patients with
moderate to severe psoriasis as measured
by [18 F]-fluorodeoxyglucose positron emis-
sion tomography-computed tomography
(FDG-PET/CT): a pilot study. Arch Dermatol
147:1031–9
A Rac1-Independent Role for P-Rex1 in Melanoblasts
Journal of Investigative Dermatology (2015) 135, 314–318; doi:10.1038/jid.2014.323; published online 11 September 2014
TO THE EDITOR
Given the recent discovery of RAC1-
activating mutations in melanoma, and
our finding that PIP3-dependent Rac-
exchanger 1 (PREX1) is overexpressed
and drives metastasis in this cancer, an
important question is to establish whe-
ther the functions of P-Rex1 are medi-
ated specifically by Rac alone (Lindsay
et al., 2011; Berger et al., 2012). Here
we describe a Rac1-independent in vivo
role for P-Rex1 through identification
and characterization of a mouse coat
color phenotype. P-Rex1 is a guanine-
nucleotide exchange factor (GEF) for
Rac, whose primary cell function is
induction of actin-mediated membrane
ruffling and lamellipodia formation at
the leading edge of cell migration
(Welch et al., 2002; Hill et al., 2005;
Barber et al., 2007).
To investigate this question we
decided to examine the role of Rac1
and P-Rex1 in melanoblast develop-
ment. Previously, we reported a ‘‘white
belly’’ phenotype of mice with Prex1
deletion (Lindsay et al., 2011). Impaired
melanoblast migration was mostly
responsible for this phenotype, with
melanoblasts lacking at the most distal
points of migration (belly and paws).
Constitutive deletion of Rac1 is
embryonically lethal, but a coat color
defect of mice with melanocyte-specific
RAC1 abrogation (Tyr::Cre Rac1fl/fl) has
also been described; these mice have a
larger belly spot on their ventral side,
suggesting that alternative Rho-GTPases
can be activated to enable melanoblast
migration to the perimeter of the
Tyr::Cre Racfl/fl white belly (Sugihara
et al., 1998; Li et al., 2011). A role for
Rac1 in proliferation was also observed,
as there was a marked reduction
of melanoblast numbers in this
phenotype. In line with these previous
studies, and because mice with melano-
cyte-specific RAC1 abrogation require
euthanization shortly after birth because
of neurological problems, we used the
same embryonic melanoblast reporter
models to assess the downstream
effects of P-Rex1 in vivo (Mackenzie
et al., 1997; Mort et al., 2010; Li
et al., 2011). Melanocyte-specific
reporter mouse strains employed were
Tyr::Cre Z/EG, which drives green
fluorescent protein expression in the
melanoblast lineage, and DCT::b-
galactosidase (otherwise referred to as
DCT-lacZ).
First, we hypothesized that, if the
effects of P-Rex1 were mediated exclu-
sively via Rac1, double mutant Tyr::Cre
Rac1fl/fl; P-Rex1 / mice would exhibit
the same coat color phenotype as
Tyr::Cre Racfl/fl mice alone. However,
Tyr::Cre Racfl/fl; P-Rex1 / mice dis-
play a dramatic alteration in coat color
phenotype from Tyr::Cre Racfl/fl mice
(n¼ 7; Figure 1a). The ventral and dorsal
coats of these mice are almost entirely
white, with hypo-pigmented limbs and
tail. Graying pigmented areas were only
observed in the head coat. We con-
cluded from this experiment that P-Rex1
and Rac1 together constitute fundamen-
tal signaling components of the mouse
coat color phenotype, with minimal
rescue of melanoblast development
conferred by other GEFs or Rho-
GTPases. It was also clear that P-Rex1
must be able to exert phenotypic effects
other than via Rac1.
To explore the Rac1-independent
effects of P-Rex1 further, we crossed
Tyr::Cre Racfl/fl; P-Rex1 / mice with
mice carrying the melanoblast reporter
DCT-lacZ transgene (methods detailed in
Lindsay et al., 2011). Relative to Tyr::Cre
Racfl/flmice or P-Rex1 / embryos
alone, Tyr::Cre Racfl/fl; P-Rex1 /Accepted article preview online 30 July 2014; published online 11 September 2014
Abbreviations: GEF, guanine-nucleotide exchange factor; OHT, 4-hydroxytamoxifen; PREX1, PIP3-
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Figure 1. P-Rex1 and Rac1 are fundamental components of a mouse coat color phenotype. (a) Ventral coats of P-Rex1 / , Tyr::Cre Rac1fl/fl and P-Rex1 / ;
Tyr::Cre Rac1fl/flmice. Final photomicrograph shows dorsal and head coat of Tyr::Cre Rac1fl/fl;P-Rex1 / mice. All mice were bred from a pure genetic
background (C57Bl6). A total of 7 Tyr::Cre Rac1fl/fl;P-Rex1 / mice were bred; as Tyr::Cre Rac1fl/fl mice have a limited life span and no breeding potential,
Tyr::Cre Rac1fl/þ mice were crossed with P-Rex1 / mice to produce approximately one in four Tyr::Cre Rac1fl/fl;P-Rex1 / pups. (b) Representative
photos of DCT-lacZ melanoblast distribution observed in wild-type (control), P-Rex1 / , Tyr::Cre Rac1fl/fl, and Tyr::Cre Rac1fl/fl;P-Rex1 / embryos at E15.5.
Black interrupted lines represent the area used for melanoblast quantification shown in c. White demarcated lines represent typical areas of melanoblast
sparing visualized for each phenotype (n¼ 3). (c) Number of melanoblasts in wild-type (Ctr), P-Rex1 / (‘P-Rex1 / ’), Tyr::Cre Rac1fl/fl (‘Rac1 f/f’), and Tyr::Cre
Rac1fl/fl;P-Rex1 / (‘Rac1 f/f P-rex1 / ’) embryos at E15.5 (X5 embryos). Lower quartile, median, and upper quartile are shown. **Po0.01 by t-test;
*Po0.05 by t-test. (d) Western blots of the primary melanocyte cell line, small interfering RNA (siRNA) treated as indicated, then treated with DMSO or
4-hydroxytamoxifen (OHT) for 5 days were probed with antibodies as indicated; Ctr, control siRNA–treated cells. (e) Growth curve of the primary
melanocyte cell line, siRNA-treated as indicated, then treated with DMSO or OHT. Each point (mean±SEM) is from three replicates of three independent
experiments. Asterisks represent difference between control siRNA–treated cells and P-Rex1 siRNA–treated cells at the same time point; Ctr, control siRNA-treated
cells.
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embryos at E15.5 displayed a substantial
reduction in melanoblast numbers across
their entire body (Figure 1b and c). To
assess whether the cause of this reduction
in melanoblast numbers could be
accounted for by decreased proliferation
± increased cell death, we next treated
our previously described primary immor-
talized Tyr::CrER2 INK4a / Racfl/fl
melanocyte cell line with short interfering
RNA to P-Rex1 (methods detailed in Li
et al., 2012). The use of this model
system also allowed us to delete Rac1
function when these cells were treated
with 4-hydroxytamoxifen (OHT). We first
used western blotting to confirm that
efficient P-Rex1 knockdown and OHT-
induced Rac deletion were achieved
(Figure 1d). There was no increase in
cleaved caspase-3 evident in the absence
of P-Rex1 and/or Rac, suggesting that the
reduced cell numbers observed in
Tyr::Cre Racfl/fl; P-Rex1 / embryos
were not accounted for by increased cell
death (Figure 1d). Growth curves and
anti-BrdU immunofluorescence of the
same cell lines confirmed that there was
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Figure 2. P-Rex1 has no additional effect on migration compared with Rac1 alone. All experiments show embryo skin explants at E15.5 (a) Combined Z-stack
confocal images of Z/EG melanoblasts from wild-type (control), P-Rex1 / , Tyr::Cre Rac1fl/fl, and Tyr::Cre Rac1fl/fl;P-Rex1 / embryos. Scale bars¼ 10mm. (b)
Representative photomicrographs showing live imaging of Z/EG melanoblasts in the skin of wild-type, P-Rex1 / , Tyr::Cre Rac1fl/fl, and Tyr::Cre Rac1fl/fl;
P-Rex1 / embryos at E15.5 (n¼3). Standard image measured at  20 magnification was 635635mm. (c) Three-hour tracks of melanoblasts from the same
genotypes. (d) Migration speed of Z/EG melanoblasts in wild-type (Ctr), P-Rex1 / (‘P-Rex1 / ’), Tyr::Cre Rac1fl/fl (‘Rac1 f/f’), and Tyr::Cre Rac1fl/fl;P-Rex1 /
(‘Rac1 f/f P-rex1 / ’) embryos (X5 embryos). **Po0.01 by t-test; *Po0.05 by t-test. (e) Z/EG melanoblast persistence, same genotypes, and annotation to that
noted in d. Error bars indicate mean ±SEM. NS, nonsignificant.
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a reduced proliferation in P-Rex1-
depleted cells, both in the presence and
absence of OHT (Figure 1e; Supple-
mentary Figure S1a and b online). Taken
together, these results suggest, in addition
to our previously reported effects of Rac1
deletion on mouse coat color, that the
loss of a Rac1-independent proliferative
effect of P-Rex1 also contributes to the
coat color phenotype observed in
Tyr::Cre Racfl/fl; P-Rex1 / mice (Li
et al., 2011).
In line with our previous character-
ization of the P-Rex1 knockout pheno-
type alone, we next decided to
delineate whether the coat color pheno-
type of Tyr::Cre Racfl/fl; P-Rex1 /
mice could also be a consequence of
reduced melanoblast migration (Lindsay
et al., 2011). To assess this, mice with
the Z/EG double reporter transgene
were crossed with Tyr::Cre Racfl/fl;
P-Rex1 /mice, driving green fluore-
scent protein expression in the melano-
blast lineage (methods detailed in
Lindsay et al., 2011; Figure 2a). Live
imaging of melanoblasts was performed
using E15.5 embryo skin from each
genotype (Figure 2b; Supplementary
Movies S1–3 online). Consistent with
our previous work, significant reduc-
tions in migration speed were observed
between wild-type, P-Rex1 / and
Tyr::Cre Racfl/fl melanoblasts (Figure 2c
and d). However, there was no signifi-
cant difference in speed between
Tyr::Cre Racfl/fl; P-Rex1 / and
Tyr::Cre Racfl/fl melanoblasts alone, sug-
gesting that there was no change in
migratory characteristics to account for
the Tyr::Cre Racfl/fl; P-Rex1 / pheno-
type (Figure 2c and d). These results
were matched by similar differences
between the same genotypes when
Euclidean distance was measured
(Figure 2e), as well as no observable
change in cell morphology evident in
Tyr::Cre Racfl/fl; P-Rex1 / compared
with Tyr::Cre Racfl/fl melanoblasts alone
(Supplementary Figure S1c online;
methods detailed in Helmy and Azim,
2012). Finally, no cell death was seen in
our melanoblast time-lapse movies of
any genotype, again suggesting that
P-Rex1 contributes to coat color
phenotype by promoting cell prolife-
ration using a Rac1-independent mech-
anism (Li et al., 2011; Supplementary
Movies S1–3 online; methods detailed
in Lindsay et al., 2011).
To conclude, we have elucidated a
proliferative role of P-Rex1 when Rac1
is deleted. As E15.5 migratory charac-
teristics are not altered in the Tyr::Cre
Racfl/fl; P-Rex1 / double mutant
embryos, this suggests that the role of
P-Rex1 in migration is almost exclu-
sively mediated via Rac1. Here we
focused on E15.5 embryos, a useful time
point to observe the late migratory
effects observed with previously
described Prex and Rac phenotypes (Li
et al., 2011; Lindsay et al., 2011). With
a greater number of embryos, we would
have performed further embryo time-
point analyses at E13.5 to ensure there
was no earlier melanoblast migratory
deficit that could contribute to this
phenotype, although even this
experiment could not completely
exclude such a possibility.
One potential Rho-GTPase, RhoG, is
a likely candidate for P-Rex1 interac-
tion: it is the most structurally similar
Rho-GTPase to Rac and has been shown
to cooperate with Rac for induction of
cell transformation (Roux et al., 1997).
Moreover, there are distinct regulatory
and functional similarities between
P-Rex1 and Vav proteins, which have
been characterized as the predominant
GEFs required for RhoG activation
(Samson et al., 2010; Lawson et al.,
2011). Further studies are underway to
investigate the phenotypes of these and
other potential Rho-GTPases in
melanoblast migration and melano-
magenesis. Given that there is now
considerable effort to generate Rac1
inhibitors, our data would suggest
functions for proteins upstream of Rac1
that may become further therapeutic
targets in melanoma. All experiments
were conducted and approved in
accordance with institutional and UK
guidelines, and all animal studies were
performed in accordance with local
regulatory guidelines.
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Rationale for the Development of Speckled
Hyperpigmentation in the Areas of Psoriatic Plaques
after Treatment with Biologic Agents
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TO THE EDITOR
We read with great interest the original
article by Wang et al. (2013) published
in this journal.
The authors investigated the effects
of proinflammatory cytokines (i.e., TNF
and IL-17) on epidermal melanocytes
and their contribution to postinflamma-
tory hyperpigmentation in psoriatic
patients.
They demonstrated that primary
human melanocytes respond to IL-17
and/or TNF stimulation forming clusters
and modulating the expression of a
broad panel of genes. In particular,
synergistic stimulation of melanocytes
with IL-17 and TNF leads to increased
expression of mitogenic cytokines and
growth factor genes (e.g., CXCL-1 and
IL-8) and downregulates the pigmenta-
tion signaling pathway and melanin
production (e.g., c-Kit, MC1R, Mitf,
Dct). There is also a significant decrease
of tyrosinase levels and cellular melanin
content.
Moreover, given the pathogenic role
of TNF and IL-17 in psoriasis, Wang
et al. investigated the pigmentation genes
in psoriatic plaques and, as expected,
they found a broad inhibition of genes
involved in melanin synthesis, catalytic
enzymes, and lineage-specific melano-
cyte transcriptional factors. Indeed,
they found overexpression of a MC1R
keratinocyte–derived antagonist (i.e.,
beta defensin 3) in psoriatic plaques.
Taken together, all these findings
suggest that the psoriatic inflammatory
milieu exerts a protective role against
melanogenesis. Recently, we (Di Cesare
et al., 2013) and others (Balato et al.,
2011) reported that psoriatic patients
have a low number of melanocytic
nevi as compared with healthy controls.
Indeed, we found that the probability of
having melanocytic nevi in psoriatic
patients was 82% lower compared with
controls even independently of personal
and medical confounders such as socio-
demographic factors, skin type and
acute and/or chronic sun exposure,
family history of cancer, and psoriasis-
associated factors, such as disease family
history, obesity, metabolic syndrome,
cigarette smoking, and alcohol consump-
tion (Di Cesare et al., 2013).
In their paper, Wang et al. (2013) also
demonstrated that psoriatic skin has an
increased number of melanocytes, with
a positive MelanA staining. They
reported that psoriatic lesional skin,
and not nonlesional or healthy control
skin, is Ki67þ /MART-1þ . This means
that, despite IL-17/TNF brake on
melanogenesis, melanocytes do not
migrate from the inflamed skin to IL-17/
TNF-free areas, but conversely they still
infiltrate the plaques, expressing CCL20
and other adhesion molecules (Wang
et al., 2013). Therapeutic neutralization
of IL-17 and TNF with biologic agents is
able to recover pigmentation signaling,
leading to postinflammatory hyper-
pigmentation in the areas correspon-
ding to the plaques that were enriched
with melanocytes. In our opinion, this is
a clue point to elucidate the mechanism
of posttherapeutic development of lenti-
gines confined to the areas of pre-
existing psoriatic plaques that has been
reported following phototherapy, topical
treatments, or biologic agents (Burrows
et al., 1994; Ana Costa et al., 2009;
Santos-Juanes et al., 2008; Martı` et al.,
2009; Bardazzi et al., 2012).
We observed the appearance of
speckled hyperpigmentation within the
psoriatic plaque areas during treatment
with biologics in six patients (2 F, 4 M;
median age: 64 years; range: 50–75
years) during the treatment with adalimu-
mab (3/6) (Figure 1), infliximab (1/6),
ustekinumab (1/6), and etanercept (1/6)
(Figure 2). A written consent for skin
biopsies and photographic documenta-
tion was obtained for each patient. All
patients were affected with moderate-
to-severe psoriasis (psoriasis area and
severity index410) and 5/6 had conco-
mitant psoriatic arthritis; 4/6 patients had
o10 nevi, and 2/6 had a total number of
nevi between 10 and 30. All patients had
received several cycles of topical (corti-
costeroids and/or vitamin D analogue,
retinoids) and systemic treatments includ-
ing ciclosporin (5/6), methotrexate (3/6),Accepted article preview online 18 July 2014; published online 21 August 2014
Abbreviation: TNF, tumor necrosis factor
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